OINDPnews

RDD Europe 2025 preview

The upcoming RDD Europe 2025 conference in Estoril, Portugal will mark the 20th anniversary of the … [Read More...] about RDD Europe 2025 preview

DDL 2024 in review

DDL 2024 drew the largest crowd ever in the 35-year history of the Drug Delivery to the Lung (DDL), … [Read More...] about DDL 2024 in review

DDL 2024 to celebrate 35 years as a leading OINDP conference

The annual Drug Delivery to the Lungs (DDL) conference will mark its 35th anniversary during this … [Read More...] about DDL 2024 to celebrate 35 years as a leading OINDP conference

The upcoming RDD Europe 2025 conference in Estoril, Portugal will mark the 20th anniversary of the first RDD Europe meeting, which took place in Paris in 2005. Co-organized by RDD Online and Aptar Pharma, the conference will take place May 6-9 and will once again include podium sessions, workshops, … [Read More...] about RDD Europe 2025 preview

HCmed names Chris Vernall as Executive VP of Business Development

Nebulizer maker HCmed has announced the appointment of Chris Vernall as its new Executive VP of Business Development. Vernall started his career as an inhalation scientist at Nanopharm and later returned to Nanopharm as Director of Business Development after a stint at Intertek. He then served in a … [Read More...] about HCmed names Chris Vernall as Executive VP of Business Development

Iconovo gets new European patent covering its ICOres inhaler platform

According to Iconovo, the European Patent Office has indicated that it will approve a patent application for an additional patent that will provide protection for Iconovo's ICOres reservoir-based dry powder inhaler platform until 2038. ICOres is already covered by patents in a number of countries, … [Read More...] about Iconovo gets new European patent covering its ICOres inhaler platform

FDA accepts Liquidia’s resubmitted NDA for Yutrepia treprostinil DPI for the treatment of PAH and PH-ILD

Liquidia Corporation announced that FDA has accepted a resubmission of its NDA for Yutrepia dry powder treprostinil for inhalation for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) with a PDUFA goal date of May … [Read More...] about FDA accepts Liquidia’s resubmitted NDA for Yutrepia treprostinil DPI for the treatment of PAH and PH-ILD

FDA issues CRL to Milestone’s NDA for Cardamyst etripamil nasal spray for PSVT

Milestone Pharmaceuticals announced that it has received a complete response letter from the FDA in regard to the company's NDA for Cardamyst etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). Milestone first submitted the NDA in October 2023 and re-submitted … [Read More...] about FDA issues CRL to Milestone’s NDA for Cardamyst etripamil nasal spray for PSVT

More news . . .

RDD Europe 2025 preview

DDL 2024 in review

DDL 2024 to celebrate 35 years as a leading OINDP conference

Latest news

RDD Europe 2025 preview

HCmed names Chris Vernall as Executive VP of Business Development

Iconovo gets new European patent covering its ICOres inhaler platform

FDA accepts Liquidia’s resubmitted NDA for Yutrepia treprostinil DPI for the treatment of PAH and PH-ILD

FDA issues CRL to Milestone’s NDA for Cardamyst etripamil nasal spray for PSVT

Other recent news